Title
Category
Credits
Event date
Cost
Caring for Patients with Advanced Cancer - Part 2: Preparing for End of Life
  • Palliative Care
  • Supportive Care Topics
  • Survivorship
  • 0.50 AAPA Category 1 CME credit
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Many health care professionals have had limited education on supportive care topics and have learned on the job. The guidelines and literature continue to advance supportive oncology care. The Coleman Supportive Oncology Collaborative developed this set of activities to describe guideline-based care and provide ways to incorporate it into patient care.Content was reviewed and updated 9/29/2023.
Recorded Presentation from the NCCN Pharmacy Updates: Hematopoietic Cell Transplantation - An Overview of Hematopoietic Cell Mobilization
  • Hematopoietic Cell Transplantation
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
It is important for practitioners to understand what factors influence successful stem cell mobilization in preparation for a transplant. They should also be familiar with the agents used in this process.
Recorded Presentation from the NCCN Pharmacy Updates: Navigating the Challenging Treatment Landscape for HIV-Associated, Non-AIDS Defining Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The incidence of non-AIDS-defining cancers (NADCs) in HIV-positive patients is increasing, and pharmacists should understand and apply pharmacokinetic parameters in order to identify potential interactions and recommend change in therapy or modifications in dosing and/or administration to aid medical oncologists in choosing the right drug at the right dose given at the right time.
Archived NCCN Tumor Boards: The Role of Molecular Profiling in the Management of Uterine Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
Determining treatment regimens for patients with uterine cancer can be challenging. With the availability of increasingly advanced imaging, surgical, and radiation therapy techniques as well as novel systemic therapy options, evidence-based guidance is needed to inform and optimize treatment decisions.
Recorded Presentation from the NCCN Pharmacy Updates: Updates in the Treatment of Kidney Cancer
  • Kidney Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The NCCN Kidney Cancer Panel recently revised the subsequent therapy recommendations providing more direction on appropriate subsequent-line options after immuno-oncology (IO) therapy or if the patient is IO therapy-naïve.
Caring for Patients With Cancer in a Post-COVID World: Expert Guidance on the Latest Data and Therapeutic Advances to Mitigate Infection Risk
  • Cancer-related Infections
  • Supportive Care Topics
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
$0.00
The goal of this activity is to improve the knowledge and competence of learners to optimize treatment for patients with COVID.
Applying NCCN Guidelines for the Treatment of CLL/SLL in Clinical Practice: The Right Agent for the Right Patient at the Right Time
  • Chronic Lymphocytic Leukemia
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
$0.00
The goal of this program is to improve the knowledge, confidence, and competence of learners in the potential clinical applications of guideline-recommended therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Archived NCCN Tumor Boards: Immune Checkpoint Inhibitors for First-Line Therapy in Esophagogastric/Esophagogastric Junction Cancer
  • Gastric/Esophageal Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
ICIs have become an advantageous treatment option for advanced or metastatic esophagogastric/EGJ cancer. Clinicians need to be aware of and understand the clinical trial data and real-world evidence supporting the use of ICIs, especially for treating MSI-H/dMMR tumors.
Recorded Presentation from the NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer
  • Breast Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion.
Recorded Presentation from the NCCN Pharmacy Updates: What Grade Are You In? The Role of Targeted Therapy in Pediatric Diffuse High-Grade Gliomas
  • Glioma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Targeted therapy is a relatively novel treatment approach to pediatric high-grade gliomas. Identifying specific molecular targets with correspondingly effective agents substantially benefits the treatment landscape and broadens therapeutic options in both the adjuvant therapy and recurrent or progressive disease setting.

Pages